The 2025-2030 World Outlook for Diabetic Gastroparesis Treatments - Image 1

Out of stock

This item is currently unavailable

The 2025-2030 World Outlook for Diabetic Gastroparesis Treatments

Subjects

Out of stock

Price data checked 6 days ago

View at Amazon

One email. No newsletter. No nudges.

Gone for 268 days. Could come back at any time — we're watching for you.

Out of stock 268 days · last price £790 · longest previous gap was 1 days

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 400 days · 400 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 400 days • 1 price levels

Days at Price

Price Analysis

Most common price: £790 (400 days, 100.0%)

Price range: £790 - £790

Price levels: 1 different prices over 400 days

Description

This study covers the world outlook for diabetic gastroparesis treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of diabetic gastroparesis treatments as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott Laboratories, Alfa Wassermann, Allergan, ANI Pharmaceuticals, Bausch Health, Boston Scientific Corporation, C. R. Bard, Cardinal Health, CINRX, Eli Lilly and Company, Endologic, Evoke Pharma, F. Hoffmann-La Roche, Fresenius Kabi, GlaxoSmithKline, Ipca Laboratories, Ironwood Pharmaceuticals, Janssen Global Services, Kimberly-Clark Corporation, Medtronic, Pfizer, Rhythm Pharmaceuticals, Salix Pharmaceuticals, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Theravance Biopharma, Vanda Pharmaceuticals, Vintage Labs, and Wockhardt. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2024).

Product Specifications

Format: paperback
ASIN: B0CZLYKZRS
Category: Books > Subjects
Domain: Amazon UK
Release Date: 03 March 2024
Listed Since: 05 May 2024

The 2025-2030 World Outlook for Diabetic Gastroparesis Treatments

Gone for 268 days. Could come back at any time — we're watching for you.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2023-2028 Outlook for Diabetic Gastroparesis Treatments in China

The 2023-2028 Outlook for Diabetic Gastroparesis Treatments in the United States

The 2023-2028 Outlook for Diabetic Gastroparesis Treatments in Japan

The 2023-2028 Outlook for Diabetic Gastroparesis Treatments for US Zip Codes

Gastroparesis: A Comprehensive Approach to Evaluation and Management

The 2026-2031 World Outlook for GLP-1 Agonists for Type 2 Diabetes

The 2023-2028 Outlook for GLP-1 Agonists for Type 2 Diabetes in China

The 2023-2028 Outlook for Diabetic Ulcers in the United States

The 2023-2028 Outlook for Diabetic Ulcers in India

The 2025-2030 World Outlook for Next Generation Diabetes Therapy and Drug Deliveries

The 2019-2024 Outlook for Diabetic Food in the United States

The 2023-2028 World Outlook for Next Generation Diabetes Therapy and Drug Deliveries

The 2023-2028 Outlook for Diabetic Ulcer Treatments in the United States

The 2023-2028 Outlook for Digestive Health Food and Drinks in the United States

Dyspepsia: Advances in Understanding and Management

The 2023-2028 Outlook for Diabetes Treatments in the United States

The 2025-2030 World Outlook for Smart Diabetes Management

The 2023-2028 Outlook for Diabetic Care Devices in India

The 2023-2028 Outlook for Diabetes Treatment Devices in India

The 2023-2028 Outlook for Diabetes Care Products in the United States

The 2013-2018 Outlook for Digestion Aids in India

The 2023-2028 Outlook for Diabetes Drugs in the United States

The 2025-2030 World Outlook for Digestive Health Supplements

Functional Dyspepsia: Evidences in Pathophysiology and Treatment